Abiopharma

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

New Form 6-K - Sol-Gel Technologies Ltd. Filed: 2025-09-04 AccNo: 0001178913-25-003223 Size: 58 KB

New Form 6-K - AC Immune SA Filed: 2025-09-04 AccNo: 0000950103-25-011258 Size: 29 KB

Immunocore to present at upcoming investor conferences

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

IFF’s Designed Enzymatic Biomaterials™ Platform Sees First Large-Scale Use in Home Care Applications

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Lillys olomorasib receives U.S. FDAs Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

New Form 6-K - Haleon plc Filed: 2025-09-04 AccNo: 0001654954-25-010382 Size: 38 KB